why choose us

First received: May 04, 2023

Clinical Trial: A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Cutaneous Squamous Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, A

Brief Summary: Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard treatments, or no standard treatments are available for the participants' cancer.The purpose of this study if to find the highest dose of MQ710 that causes few or mild side effects in participants with a solid tumor cancer diagnosis.

Read more